11.14.13
Langhorne, Pa.-based wound care technology company Alliqua Inc. snagged a cool $1 million in financing from Crossover Healthcare Fund LLC. The financing is to be used “to pursue the company’s key initiatives in the wound care space.”
The financing comes in the form of units consisting of 250,000 shares of series A preferred stock that are convertible into Alliqua common stock.
“We are pleased to welcome Crossover Healthcare Fund LLC as our newest investor,” said Brian M. Posner, Alliqua’s chief financial officer. “This financing will help us advance our sales and marketing initiatives for our line of 510(k) FDA-approved hydrogel products for wound care under the SilverSeal brand, as well as the Sorbion Sachet S and Sorbion Sana wound care products.”
In September 2013, Alliqua signed a long-term agreement with Sorbion GmbH & Co. KG to distribute the Sorbion Sachet S, Sorbion Sana and new products with hydrokinetic fibers as primary dressings. Sorbion hydroactive wound care products will be distributed exclusively by Alliqua throughout all of the Americas.
Alliquais a biopharmaceutical company focused on the development of proprietary transdermal wound care and drug delivery technologies. Alliqua’s technology platform produces hydrogels, a 3-D cross-linked network of water-soluble polymers capable of numerous chemical configurations.
The financing comes in the form of units consisting of 250,000 shares of series A preferred stock that are convertible into Alliqua common stock.
“We are pleased to welcome Crossover Healthcare Fund LLC as our newest investor,” said Brian M. Posner, Alliqua’s chief financial officer. “This financing will help us advance our sales and marketing initiatives for our line of 510(k) FDA-approved hydrogel products for wound care under the SilverSeal brand, as well as the Sorbion Sachet S and Sorbion Sana wound care products.”
In September 2013, Alliqua signed a long-term agreement with Sorbion GmbH & Co. KG to distribute the Sorbion Sachet S, Sorbion Sana and new products with hydrokinetic fibers as primary dressings. Sorbion hydroactive wound care products will be distributed exclusively by Alliqua throughout all of the Americas.
Alliquais a biopharmaceutical company focused on the development of proprietary transdermal wound care and drug delivery technologies. Alliqua’s technology platform produces hydrogels, a 3-D cross-linked network of water-soluble polymers capable of numerous chemical configurations.